The two FlowOx™ therapy trials described earlier had a follow up of three months, the observed probabilities from the clinical follow up and published evidence was used to populate the transition probabilities. Where there was insufficient data, point estimates were derived from published literature [3,32]. The relative risk and effects of disease progression were derived from the study data and are presented with the transition probabilities in Table D in S1 Appendix.

The model assumed all participants were at the symptomatic phase of PAD (progressive state) at the beginning of the model and then progressed through the model using the given transition probabilities. Cost and health outcomes were computed from the distributed simulation.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.